Clinical observation on pemetrexed disodium in the treatment of advanced pulmonary adenocarcinoma

VernacularTitle:培美曲塞治疗晚期肺腺癌的临床观察
Author: Wei GUO ; Ruifen TIAN ; Xia ZHANG ; Fangfang SHEN ; Qiaoli REN ; Xia SONG
Publication Type:Journal Article
Keywords: Carcinoma,non-small-cell lung; Pemetrexed Disodium; Adenocarcinoma; Efficacy
From: Cancer Research and Clinic 2013;(1):12-14
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and drug-related toxicities of pemetrexed disodium in the treatment of advanced pulmonary adenocarcinoma.Methods A total of 41 patients who had received pemetrexed disodium and cisplatin therapy were retrospectively reviewed.The patients were given respectively pemetrexed disodium (500 mg/m2,1st day) and cisplatin (200 mg/m2,1-4 day) until disease progressed.The clinical outcomes and adverse reactions were observed.Results The CR rate was 7.3 ％ (3/41),PR rate was 22.0 ％ (9/41),SD rate was 31.7 ％ (13/41),PD rate was 39.0 ％ (16/41),the DRR was 29.3 ％ (12/41),DCR rate was 61.0 ％ (25/41),the median PFS was 5 months.The age,sex,smoking history,staging and timing of treatment had not the statistics difference on ORR and DCR.The sex,smoking history,staging and timing of treatment had not the statistical difference on PFS (P ＞ 0.05).The main toxicities were fatigue,nausea,vomiting and myelosuppression.Conclusion The pemetrexed disodium and cisplatin are feasible and welltolerated for advanced pulmonary adenocarcinoma patients.